Received Feb 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
slight cough; breathing labored frequently; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of cough in a male patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. In JAN-2025, the patient received Arexvy. On an unknown date, less than a week after receiving Arexvy, the patient experienced cough (Verbatim: slight cough) and labored breathing (Verbatim: breathing labored frequently). The outcome of the cough and labored breathing were not reported. It was unknown if the reporter considered the cough and labored breathing to be related to Arexvy. It was unknown if the company considered the cough and labored breathing to be related to Arexvy. Additional Information: GSK Receipt Date: 01-FEB-2025 This case was reported by a patient via interactive digital media. The patient 's wife reported that her husband got Arexvy shot 6 days ago and had slight cough and breathing labored frequently. She enquired how long it would last. The follow-up could not be possible as no contact details were available